Spyre Aims to Remake IBD Care with Twice-Yearly Treatment

STOCKHOLM, SWEDEN – February 18, 2026 – Biotechnology firm Spyre Therapeutics has unveiled promising new data that could fundamentally alter the lives of millions living with Inflammatory Bowel Disease (IBD). At the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), the company presented findings suggesting its investigational drug, SPY003, could potentially be administered as infrequently as once every six months, a dramatic departure from the current landscape of frequent injections and infusions.

This announcement, coupled with new details on an innovative combination therapy trial, signals Spyre's ambitious strategy to redefine the standard of care for chronic inflammatory conditions like Crohn's disease and ulcerative colitis. The company is not only aiming to reduce the significant treatment burden for patients but also to achieve deeper, more durable remission by tackling the disease from multiple angles.

The Promise of a Twice-Yearly Shot

The centerpiece of Spyre's presentation was the interim Phase 1 data for SPY003, a long-acting monoclonal antibody targeting IL-23. The IL-23 pathway is a clinically validated driver of inflammation in IBD, and several approved drugs, such as AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya, have proven the effectiveness of blocking it. However, Spyre is aiming to take this approach a significant step further.

The data, presented from a 20-week follow-up, showed SPY003 was well-tolerated with a favorable safety profile. Crucially, it demonstrated a differentiated pharmacokinetic profile, boasting an estimated half-life of approximately 85 days. This is more than three times longer than some established IL-23 inhibitors on the market, which typically require dosing every 8 to 12 weeks. This extended half-life is what underpins the potential for a quarterly or even a twice-yearly subcutaneous maintenance dosing schedule.

For patients, the implications are profound. Living with IBD often involves a relentless schedule of self-injections or hours-long intravenous infusions. A treatment that requires only two injections per year could dramatically improve quality of life, reduce the psychological burden of the disease, and increase treatment adherence—a critical factor for long-term disease control.

“We are excited to share follow-up data out to 20 weeks from our Phase 1 study of SPY003,” said Deanna Nguyen, M.D., SVP of Clinical Development at Spyre, in a statement. “The data showed SPY003 was well tolerated, had a differentiated PK profile supporting quarterly or twice-yearly dosing, and demonstrated targeted biological activity via a reduction in downstream cytokines.”

Beyond Monotherapy: A Strategic Bet on Combinations

While a less frequent, highly effective monotherapy would be a major win, Spyre’s vision extends further. The company is betting that the future of IBD treatment lies in combination therapies that target multiple inflammatory pathways simultaneously. To that end, it also presented details on its innovative SKYLINE-UC platform trial.

Described as the first platform study of its kind in ulcerative colitis, SKYLINE-UC is designed to efficiently test three of Spyre’s long-acting antibodies—SPY001 (targeting α4β7), SPY002 (targeting TL1A), and SPY003 (targeting IL-23)—both as single agents and in various combinations. This trial design allows the company to rapidly assess which regimen provides the best efficacy and safety, accelerating the path to identifying a superior treatment.

This strategy is bolstered by preclinical data also presented at ECCO, which demonstrated that a combination of anti-TL1A and anti-IL-23 therapies provided superior efficacy in a mouse model of colitis compared to either drug alone. TL1A is another key inflammatory mediator that has become one of the hottest targets in IBD drug development. By inhibiting both IL-23 and TL1A, Spyre hopes to deliver a one-two punch that could induce remission in a larger proportion of patients, including those who have failed other advanced therapies.

Dr. Nguyen noted, “Preclinical data demonstrating that dual targeting of TL1A and IL-23 can provide superior efficacy compared to either agent alone... highlight the strength of our antibody portfolio and our strategy to redefine the standard of care in IBD.”

Navigating a Crowded and Lucrative Market

Spyre’s ambitious strategy is unfolding within one of the most competitive and valuable sectors of the pharmaceutical industry. The IBD biologics market is projected to exceed $60 billion annually by 2026, dominated by pharmaceutical giants with blockbuster drugs. The anti-IL-23 class alone is a multi-billion dollar market, and the race to develop the first approved anti-TL1A inhibitor is intense, with major players like Merck and Roche in late-stage trials.

In this crowded field, Spyre is carving out a distinct niche. Its strategy is not just to compete on mechanism of action but to win on convenience and superior efficacy through combinations. By engineering its entire portfolio for extended half-life, the company ensures that any potential combination therapy could maintain a highly convenient, infrequent dosing schedule. This dual focus on powerful combinations and patient-friendly administration could be a potent market disruptor.

The SKYLINE-UC trial, which began in mid-2025, represents a critical test of this strategy. Initial open-label data from the monotherapy arms are anticipated in mid-2026, with the full placebo-controlled results for both single agents and combinations expected in 2027. The outcomes of this trial will be closely watched by investors, competitors, and, most importantly, the patient community. While the road through clinical development is long and fraught with uncertainty, the data presented in Stockholm provides a compelling glimpse into a future where managing IBD could become a far less intrusive part of a patient's life.